Granted Patent
B2
US 8,748,597 · App. 13/909,830 · Granted Jun 10, 2014
2,4-pyrimidinediamine compounds and their uses
Inventors:
Rajinder Singh (Belmont, CA); Ankush Argade (Foster City, CA); Catherine Sylvain (San Mateo, CA)
Assignee:
Rigel Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
Claims (1)
1. 6-amino-2,2-difluoro-4H-benzo[1,4]oxazin-3-one.
Assignments (2)
SECURITY INTEREST
Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 4, 2013
From: SINGH, RAJINDER; ARGADE, ANKUSH; PAYAN, DONALD G.; MOLINEAUX, SUSAN; HOLLAND, SACHA J.; CLOUGH, JEFFREY; KEIM, HOLGER; BHAMIDIPATI, SOMASEKHAR; SYLVAIN, CATHERINE; LI, HUI; ROSSI, ALEXANDER B.
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 031344/0393 →
Continuity (10)
Provisional Application
60353333
· Feb 1, 2002
Provisional Application
60353267
· Feb 1, 2002
Provisional Application
60399673
· Jul 29, 2002
Provisional Application
60434277
· Dec 17, 2002